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“When nothing is sure, everything is possible.” Margaret Drabbler   
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Resumo 
 
Cada vez mais, o cancro representa um crescente problema de saúde pública a 
nível global e estima-se que em 2025 o número de novos casos atinja os 19,3 milhões 
devido ao crescimento e envelhecimento da população mundial.  
O cancro do pulmão é a principal causa de morte por doença oncológica no mundo. 
A maioria dos cancros de pulmão (80%) são cancros de pulmão de não-pequenas-células 
(CPNPC). Destes, mais de 65% dos pacientes apresenta doença localmente avançada ou 
metastática. É operável se diagnosticado em estadios precoces e a taxa de sobrevivência 
a cinco anos é aproximadamente 50%-70%. No entanto, a taxa de sobrevivência a cinco 
anos diminui para 2%-5% para os pacientes cuja doença já disseminou aquando do 
diagnóstico. Embora o diagnóstico precoce possa salvar vidas, os atuais métodos de 
rastreio para os indivíduos de alto-risco não demonstraram melhorias na sobrevivência. É, 
então, essencial que se desenvolva uma abordagem não invasiva de rastreio baseada em 
biomarcadores moleculares que permita uma melhoria na avaliação de risco e um  
diagnóstico precoce. 
Um possível marcador é o CADM1 (Cell Adhesion Molecule 1), um gene supressor 
tumoral localizado na região 11q23.2 que codifica para uma glicoproteína da superfamília 
das imunoglobulinas cuja expressão se encontra diminuída em muitos tumores sólidos. 
Este gene está associado com a supressão tumoral e também com a diminuição da 
metastização, especialmente em CPNPC. Na grande maioria dos casos a diminuição da 
expressão do CADM1 parece resultar do silenciamento por metilação do promotor.  
Com o presente trabalho propusemo-nos a avaliar a utilização de níveis de 
expressão de Cadm1 como biomarcador de diagnóstico e/ou prognóstico de CPNPC. Para 
validar o Cadm1 como um marcador de diagnóstico, elaborou-se um estudo de caso-
controlo de base hospitalar, usando amostras de sangue provenientes de 89 doentes com 
CPNPC e 52 indivíduos saudáveis. Numa segunda fase, realizou-se um estudo de follow-
up a 89 doentes com CPNPC para avaliar a associação entre os níveis de expressão de 
Cadm1 no sangue periférico, a progressão da doença e o outcome clínico. 
Ao compararmos os perfis de expressão de Cadm1 entre os indivíduos saudáveis 
e os indivíduos com CPNPC, observamos claras diferenças entre os grupos. Indivíduos 
com CPNPC apresentam níveis mais baixos de expressão de Cadm1 comparativamente 
com indivíduos saudáveis que apresentam níveis mais elevados. (OR=2,147; 
IC95%=1,068-4,32; p=0,031), não estando estas diferenças relacionadas com o sexo do 
indivíduo (HR=0,401; IC95%= 0,181-0,887; p=0,024).  
Não foram encontradas diferenças nos níveis de expressão de Cadm1 entre os 
vários estadios da doença (nem entre estadios iniciais e estadios avançados nem entre 
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não metastizados e estadios metastizados).   
Os níveis de expressão de Cadm1 no sangue periférico parecem influenciar apenas 
a sobrevivência a um ano dos indivíduos não metastáticos e não dos indivíduos com 
tumores em estadio IV. Indivíduos com tumores não metastáticos e baixos níveis de 
expressão de Cadm1 em circulação apresentam uma pior taxa de sobrevivência do que 
aqueles que têm tumor não-metastático, mas elevados níveis de Cadm1 (p=0,016). 
Apesar de os níveis de expressão de Cadm1 no sangue periférico aparentemente 
não representarem um bom marcador de prognóstico, os nossos resultados suportam o 
seu uso como biomarcador de diagnóstico apresentando uma sensibilidade de 57,3%, 
especificidade de 61,5%, VPP de 72% e VNP de 54%.  
Não existindo à data um marcador ideal para diagnóstico de cancro do pulmão e 
visto que os métodos utilizados apresentam maiores custos, maiores riscos de indução de 
efeitos secundários e impossibilidade de aplicação em toda a população, concluímos, com 
base nos nossos resultados, que o Cadm1 poderá ser um potencial biomarcador de 
diagnóstico de CPNPC através de uma simples amostra de sangue.    
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Abstract 
 
More and more, cancer has become an emerging public health problem worldwide 
and it is estimated that there will be 19.3 million new cases per year by 2025 due to growth 
and ageing of the global population. Lung cancer is the leading cause of cancer-related 
death worldwide. Most lung cancers (80%) are non-small-cell lung cancers (NSCLC) and 
of these, more than 65% of the patients present with locally advanced or metastatic disease. 
When diagnosed in an early stage it's operable and the five-year survival rate is 
approximately 50%–70%. However, the five-year survival rate drops to 2%–5% for patients 
whose cancers are diagnosed after their tumors have spread distantly. Although early 
detection can save lives, the current screening tests for high-risk individuals have not 
resulted in improvements in disease-specific survival. It has become imperial to develop a 
non-invasive approach based on molecular biomarkers that may significantly improve the 
assessment of risk and early diagnosis. 
One candidate marker is cell adhesion molecule 1 (CADM1), a putative tumor 
suppressor gene located in 11q23.2 region, which encodes a glycoprotein of the 
immunoglobulin superfamily and that is found to be downregulated in many solid tumors. It 
has been related both with suppression of tumorigenesis and decreased metastization, 
especially in non-small cell lung cancer (NSCLC) and in most cases its downregulation 
appears to be silencing by promoter methylation. 
The aim of the present study was to evaluate if Cadm1 expression levels can be 
used as biomarker for diagnosis and/or prognosis for NSCLC. To evaluate the potential of 
using Cadm1 expression levels in peripheral blood as a diagnostic marker for NSCLC we 
conducted a hospital-based case-control study using blood samples from 89 NSCLC 
patients and 52 healthy individuals. In a second phase we performed a follow-up study with 
89 NSCLC patients to evaluate the association between Cadm1’s expression levels in 
peripheral blood and disease progression and clinical outcome.  
When we compared the expression profiles of healthy individuals against NSCLC 
patients, we observed clear differences of expression between both groups. Cadm1 
presents lower expression levels in NSCLC patients compared to the higher levels 
measured in healthy individuals (OR=2.147; CI95%=1.068-4.32; p=0.031). Also, we 
observed that this differences are independent of gender (HR=0.401; CI95%= 0.181-0.887; 
p=0.024).  
When studying the association between Cadm1’s expression levels and disease 
progression we didn’t find any differences between early stages and more advanced stages, 
or between non metastatic and metastatic tumors.  
Furthermore, Cadm1’s expression levels in peripheral blood only appears to 
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influence one-year survival in non-metastatic patients and not in those who have stage IV 
tumors. Patients with non-metastatic tumors and low Cadm1’s expression levels in 
circulation have lower survival rates that those who have non-metastatic tumor but high 
Cadm1’s expression levels (p=0.016). 
Even though it appears that Cadm1’s expression levels in peripheral blood aren’t a 
good prognostic marker, our results support the potential of using Cadm1 as a diagnostic 
biomarker with a sensibility of 57.3%, specificity 61.5%, PPV of 72% and NPV of 54%.  
Since there isn’t an ideal screening method for lung cancer and the methodologies 
used are either expensive, have side effects, or are not accessible or applicable to every-
body we conclude, based on these results, that Cadm1 may become a potential biomarker 
for NSCLC through a simple blood test.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
Introduction  
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1. Introduction 
 
1.1. Cancer: Epidemiology and general concepts 
 
More and more, cancer has become an emerging public health problem worldwide 
and it is estimated that there will be 19.3 million new cases per year by 2025 due to growth 
and ageing of the global population [1]. At present time, it represents the first and the third 
cause of death in the developed countries and in the less developed countries, respectively 
[2]. According to GLOBOCAN 2012 - the International Agency for Research on Cancer 
(IARC) online database - there were 14.1 million new cancer cases, 8.2 million cancer 
deaths in 2012, compared to 12.7 million and 7.6 million, respectively, registered in 2008 
[1]. Estimates prevalence rates for 2012 show that there were 32.6 million people alive (over 
the age of 15 years) who had had a cancer diagnosed in the previous five years [3].  
The term 'cancer' defines over one hundred different diseases that can arise from 
virtually any tissue or organ in the body. It is a heterogeneous disease, with different etiology 
and natural history that develops through the interactions between environmental and ge-
netic factors, and involves deregulation of multiple pathways responsible for the fundamen-
tal cell processes, such as death, proliferation, differentiation and cell migration [4]. Hana-
han and Weinberg proposed that cancer cells acquire six biological capabilities during the 
multistep development of human tumors that are shared by nearly all cancers and are con-
sidered to represent the hallmarks that govern the conversion of normal cells into cancer 
cells. Those include growth signal autonomy, insensitivity to anti-growth signals, apoptosis 
evasion, replicative immortality, angiogenesis induction and tissue invasion and metastasis. 
Conceptual progress in the last decade has added two emerging hallmarks of potential 
generality to this list - reprogramming of energy metabolism and evading immune destruc-
tion. In addition to cancer cells, tumors exhibit another dimension of complexity for they 
contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of 
hallmark traits by creating the ‘‘tumor microenvironment’’ [5]. 
The process of carcinogenesis is very complex and involves a progressive 
accumulation of genetic alterations that lead to the transformation of a normal cell to a 
neoplastic cell [5]. Carcinogenesis can be divided in three main stages: Initiation, promotion 
and progression.  
The initiation process consists on the acquisition of non-lethal genetic lesions by the 
somatic cells, caused by carcinogens (chemical, physical or biological), by epigenetic 
alterations or by inherited germline alterations [6]. If this cell is stimulated by promoting 
agents like chemicals or hormones and isn’t able to repair the damages, there is an 
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accumulation of genetic alterations that provides a selective advantage for these cells over 
normal cells. This is the promotion stage: there is a selective clonal expansion of initiated 
cells which results in a larger population of cells that are at risk of further genetic changes 
and malignant conversion [7]. Tumor progression comprises the expression of the malignant 
phenotype and the tendency of malignant cells to acquire more aggressive characteristics 
over time. During this process, and through interaction with environmental factors, there 
may occur genetic and epigenetic alterations that allow the activation of proto-oncogenes 
and inactivation of tumor suppressor genes (TSGs). Subsequently, multiple events occur 
that result in the disruption of processes such as cell proliferation and apoptosis, which in 
turn lead to the growth and development of malignancies. The mutations acquired during 
neoplastic development make the cells less sensitive to apoptotic signals, cell growth stop 
and destruction by the immune system. Cumulatively, the self-sufficiency of these cells in 
growth factors provides them with greater proliferative capacity, angiogenesis and invasive 
potential. These factors combined with increase in inflammation, genomic instability and cell 
energy deregulation, favor cancer development and systemic dissemination, enhancing the 
metastatic process [8]. 
Even though there has been new developments and achievements in the field of 
Oncology, either in the early detection of some neoplasia and in the development of new 
treatments more effective in disease management, the numbers are still increasing and the 
acquired resistance to these treatments has become a difficult obstacle to overcome. 
 
1.2. Lung Cancer 
 
Lung cancer has been the most common cancer in the world for several decades. 
There were estimated to be 1.8 million new cases in 2012 (12.9% of the total). The disease 
remains as the most common cancer in men worldwide (1.2 million, 16.7% of the total) with 
the highest estimated age-standardized incidence rates in Central and Eastern Europe 
(53.5 per 100,000) and Eastern Asia (50.4 per 100,000), in 2012. In women, the incidence 
rates are generally lower (approximately 0.6 million, 8.8% of the total) and the geographical 
pattern is a little different, mainly reflecting different historical exposure to tobacco smoking. 
Furthermore, lung cancer is the most common cause of death from cancer worldwide, 
estimated to be responsible for nearly one in five deaths (1.59 million deaths, 19.4% of the 
total) which is more than breast, colon and prostate cancer combined [1, 2]. 
In Portugal, lung cancer is the fourth most common neoplasia (4192 cases, 8.5% of 
total), but has the second highest mortality rate (3441 deaths, 14.3% of the total) following 
closely the 15.7% death rate caused by colorectal cancer [9]. 
According to American Cancer Society estimates, the 1- and 5-year relative survival 
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rates for lung cancer cases diagnosed during 2003-2009 were 43% and 17%, respectively 
[10]. The majority of lung cancer cases in men (~85%) and approximately 47% of lung 
cancer cases in women are estimated as being the consequence of tobacco smoking [11]. 
Primary prevention should continue to be a major focus of public health campaigns for there 
is overwhelming evidence that tobacco smoking is the major cause of lung cancer not only 
based on epidemiological studies. Lung tumors of smokers frequently contain a typical, 
though not specific, molecular footprint in the form of G:C>T:A mutation in TP53 gene which 
are probably caused by benzo[a]pyrene one of the many carcinogens in tobacco smoke 
[11].  
However, there are other factors that may play a role in susceptibility to lung cancer 
or modulate the development of the neoplasia. Occupational exposure to carcinogens like 
arsenic, asbestos and other chemicals, pulmonary chronic disease, environmental pollution, 
pulmonary tuberculosis or even family history, viruses, and auto-immune diseases are 
considered to be possible risk factors, but further studies are necessary to clarify their 
association with lung cancer [11].  
One of the biggest problems associated with poor survival in lung cancer cases is 
that most patients present with metastatic disease at time of diagnosis (~65%) [12, 13]. 
Metastasis is a multistep process in tumor development that culminates in a systemic 
spread of cancer cells. For reasons still unclear, some cells from the primary tumor suffer 
molecular alterations that causes them to separate from the tumor and enter circulation and 
invade another organ where a new tumor starts developing. Treatment against metastasis 
is still very poor because of the heterogeneity of the metastasis since the same type of 
tumor can develop metastasis in different sites, and even in the same tumor, different cells 
have a potential to metastasize. 
A correct evaluation of the histologic subtype and staging at the time of diagnosis is 
necessary for treatment and patient’s prognosis [14]. Staging for lung tumors is according 
to the TNM system, proposed by the American Joint Committee on Cancer (AJCC), that 
classifies the tumor according to its size and invasive potential (T), with the involvement of 
regional lymph nodes (N) and the absence or presence of long distance metastasis (M) [14-
16].  
Even though 50% of lung carcinomas exhibit more than one major histological type, 
two main categories are distinguished: small cell lung cancer (SCLC) accounting for about 
20% of lung cancer cases, and non-small cell lung cancer (NSCLC) that comprises a 
number of histological subtypes representing near 80% of lung cancers [11]. 
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1.3. Non-small cell lung cancer  
 
NSCLC is representative of many different histological subtypes of lung cancer. The 
most frequent histological subtypes are: large cell/undifferentiated carcinomas; squamous 
cell carcinomas (SCC) and adenocarcinomas [11].  
This neoplasia is often asymptomatic in early stages. As a result, of all the patients 
with NSCLC, more than 65% present with locally advanced or metastatic disease at 
diagnosis [12]. 
When diagnosed in an early stage it's operable and the five-year survival rate is 
approximately 50%–70%. However, the five-year survival rate drops to 2%–5% for patients 
whose cancers are diagnosed after their tumors have spread distantly [17]. Until the late 
1990s, treatment of advanced lung cancer was based on platinum combination therapy, 
irrespective of histological subtype and without any option for further lines of treatment [18].  
Since then, the introduction and development of cytotoxic drugs (such as 
gemcitabine, vinorelbine, docetaxel, and paclitaxel) and patient selection based on the 
recognition that different histological subtypes and driver mutations determine the biology 
of these malignancies and predict drug efficacy, changed the treatment of NSCLC. This 
resulted in improvement of overall survival up to 12 months and longer in clinical studies 
[18].  
Even though the new approach to NSCLC treatment improved the overall survival 
there has been only a minor improvement in five-year survival from lung cancer in the last 
few decades. It's obvious that the sooner it's caught, the better the outcome. 
According to the World Health Organization, early diagnosis and screening are the 
two main components for early detection. Early diagnosis - or the awareness of early signs 
and symptoms - is particularly relevant when there are no effective screening methods or 
no screening and treatment interventions implemented. Screening aims to identify 
individuals with abnormalities suggestive of a specific cancer or pre-cancer and refer them 
promptly for treatment or when feasible for diagnosis and treatment. 
Although early detection can save lives, screening tests for high-risk individuals 
using sputum cytology or chest X-rays have not resulted in improvements in disease-
specific survival [19, 20].  Annual screening with low-dose CT scanning was associated with 
a significant reduction in lung cancer mortality in one large study of high-risk individuals [21]. 
However, more data are needed on the cost effectiveness of screening that takes into 
account the frequency of screening and both the benefits and harms (such as false positives 
and over-diagnosis) before recommendations can be made for large-scale screening 
programs [21]. Microarray-based gene expression profiling has successfully been used in 
clinical cancer research to sub-classify cancer entities, to predict prognosis or response to 
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therapy, and to identify underlying mechanisms of tumor development but again, more data 
are needed [22]. 
Until the last decade, NSCLC was considered a single disease, and systemic 
treatment of metastatic NSCLC was limited to platinum-based chemotherapy doublets 
resulting in approximately 20% response rates and median survival of 8 months [23]. 
Since then, molecular diagnosis has been playing a major role in understanding the 
pathogenesis, diagnosis and treatment of lung cancer which has led to the identification of 
biomarkers in NSCLC [24]. 
The clinical challenge, therefore, is to develop a non-invasive approach based on 
molecular biomarkers that may significantly improve the assessment of risk and early 
diagnosis. 
 
1.4. Biomarkers 
 
According to the National (American) Cancer Institute, a biomarker is “a biological 
molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal 
process, or of a condition or disease”. They typically differentiate an affected patient from a 
person without the disease and can be detected in the circulation (whole blood, serum or 
plasma), excretions or secretions (stool, urine, sputum), and thus easily assessed non-
invasively and serially, or can be tissue-derived and require either biopsy or special imaging 
evaluation. 
Biomarkers can be divided into: Diagnostic biomarkers; prognostic biomarkers; 
treatment biomarkers and prevention biomarkers.  
Diagnostic biomarkers, also called predictive biomarkers (targets for diagnostic 
intervention), are identified by characterizing key mutations and molecular pathways 
involved in tumor development and proliferation. They help optimize therapy decisions by 
providing information about the likelihood of a response to a chemotherapeutic intervention 
[25]. Prognostic biomarkers are assigned to a specific tumor type by determining the 
occurring polymorphism, mutation or the change in DNA methylation or gene expression, 
or by detecting the presence of specific miRNA molecules or CTCs in the peripheral blood. 
They enable the monitoring of the advances in anti-cancer therapy, the assessment of the 
stage of the tumor and its potential malignancy, as well as the prognosis of disease 
remission in every case individually [25]. Treatment and prevention biomarkers are 
subgroups that require more accurate molecular analysis to guide individual therapy by 
identifying patients with different outcome risks (such as recurrence of the disease) [25]. 
Diagnostic and prognostic biomarkers particularly aid in identifying who is at risk, 
diagnose at an early stage, select the best treatment modality and monitor response to 
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treatment [26].  
Over the last decade, the oncology field has witnessed significant advances in 
understanding these differences specific to a type of cancer or between patients, and 
instead of treating a particular histology, or organ system, it is now clear that a cancer with 
a specific histology represents a constellation of diseases with distinct molecular profiles 
and sensitivities to treatment (Figure 1). Personalized therapy based on patient's individual 
biologic and molecular profile is a promising approach to optimize efficacy in the available 
agents. This understanding has allowed us to deliver targeted therapy, which utilizes agents 
that affect a known aberrant pathway or molecular target in the cancer cell or tumor 
microenvironment. The treatment is no longer based on a “one drug fits all” approach but 
instead a more personalized strategy where treatment is driven by biomarker expression 
profiles [27-29].  
  
 
Mutations in specific genes that affect DNA repair in germline cells may be inherited 
and sometimes a mutation in only one allele is enough to impair the whole repair system. 
This is the case, for example, of mutated BRCA2 gene in breast cancer. Patients identified 
with mutations in genes like these could, and should, undergo regular screening 
examinations to allow earlier detection of any tumor that might be growing asymptomatically 
[30].  
TP53 mutations are the most frequent in all histological types of lung cancer. This 
Figure 1 Evolution of lung cancer histology over time. The colors denote different histological subtypes [18] 
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gene encodes the p53 protein that plays multi anti-proliferative roles in particular in 
response to genotoxic stress. Inactivating TP53 mutations (mostly missense mutations) are 
detected in up to 50% of all human tumors [31].  Although p53 is not a typical cancer-specific 
antigen, its central role in the control of cell growth and apoptosis and frequent mutations in 
tumors make p53 a unique target for cancer therapy. 
 
Some of these biomarkers are the result of mutations in genes like EGFR, K-RAS, 
HER-2, BRAF, or translocations like the echinoderm microtubule-associated protein-like 4-
anaplastic lymphoma kinase (EML4-ALK) translocation and their frequencies are 
represented in (figure 2) [32].  
 
Figure 2 Molecular subsets of lung adenocarcinoma [32]. 
 
The following are three of the most promising molecular biomarkers studied in lung 
cancer. The Kirsten Rat Sarcoma (KRAS) gene was first described in human cancers in 
1980s, where it was found to be active in tumor tissue but not in normal host tissues [33]. 
Mutations have been found in approximately 17% of all NSCLC, and are seen in 25%-34% 
of adenocarcinomas and non-squamous tumors, but are rarely seen in squamous cell 
carcinomas. However, a multivariate analysis looking at prognostic factors found that K-
RAS mutational status was a weak prognostic factor (relative risk 0.641, P=0.066) [34, 35]. 
The Epidermal Growth Factor Receptor (EGFR) is one of a family of receptors that 
is overexpressed in about 10%-15% of cases. It has been proved that somatic mutations in 
exons 19 or 21 of the gene are related to tumor sensitivity to therapies with tyrosine kinase 
inhibitors (TKIs) such as gefitinib or erlotinib [36, 37].  
Anaplastic lymphoma kinase (ALK) gene rearrangement was first reported in 2007 
by Soda et al. In this translocation, a deletion and translocation in chromosome 2p brings 
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the EML4 gene in conjunction with ALK receptor tyrosine kinase, making a fusion protein in 
which the tyrosine kinase activity is permanently turned on. This translocation is detected 
in approximately 5% of patients with adenocarcinoma and are usually seen in non-smokers 
or very light smokers [38]. 
Unfortunately, the number of patients for whom targeted therapy is suitable is still 
very small (Figure 2). The access to tumor tissue for biomarker assessment and de novo 
molecular and genomic tumor heterogeneity (that may be further increased during the 
biomarker-driven therapy) remains a serious challenge. Ongoing research in detection of 
cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs) may become 
clinically relevant alternatives for tumor biopsy that will provide measurements of the total 
tumor burden as well as identify mutations arising during therapy that may be responsible 
for development of acquired resistance [32].  
 
1.5. CADM1 
 
Cell Adhesion Molecule 1(CADM1) is also referred to as IGSF4, TSLC1, SgIGF, 
SynCAM, NECL2 according to the different functions in different tissues [39-43]. 
In 1998, Murakami et al observed that loss of heterozygosity (LOH) on chromosome 
11q23 occurred in patients with non-small cell lung carcinomas (NSCLC) [44]. In 1999, a 
new member of ImunoGlobulin SuperFamily (IGSF) was isolated from that region and 
named as IGSF4 [39]. In 2001, by combinatorial analyses of YAC transfer into human 
NSCLC cells with a tumorigenicity assay in nude mice using A549 cell line, the IGSF4 gene 
was identified as a tumor suppressor in NSCLC and was renamed as Tumor Suppressor of 
Lung Cancer 1(TSLC1) [40, 41].  In the same year and the next, researchers of testis and 
brain found that this molecule played a significant role in spermatogenic-cell attachment 
and synapse formation. Accordingly, IGSF4/TSLC1 was renamed as Spermatogenic 
Immunoglobulin Superfamily (SgIGSF) and Synaptic Cell Adhesion Molecule (SynCAM), 
respectively [43, 45].  In 2003 Ito et al. found a role for the molecule in mast-cell adhesion 
in the course of mast cell research [46].  
This region encodes an immunoglobulin superfamily cell adhesion molecule (IgCAM) 
homologous with the neural cell adhesion molecule and is involved in Ca2+-independent 
cell-cell adhesion and cell signal transduction [47, 48].  
Cadm1 is a type I transmembrane glycoprotein located in the chromosome 11q23.2, 
it has 442 aminoacids with a molecular weight of 75 kD in normal epithelium including the 
lung, 70 kD in the brain, and approximately 100 kD in the testis. This difference in molecular 
weight appears to be a result of post-translational modification, in addition to a variation in 
splicing [49, 50]. 
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At the N-terminal there is a signal sequence followed by three Immunoglobulin-like 
domains that interact through a homo and heterophilic manner. There is a transmembrane 
domain and a small cytoplasmic domain as shown in figure 3 [40, 45, 46, 51]. 
 
Figure 3 Schematic representation of the structure of CADM1. CADM1 contains from the NH2-terminal to the 
COOH-terminal signal peptide, three Ig domains, a transmembrane domain, protein 4.1 binding motif and PDZ 
binding motif [52].  
. 
The overall structure of CADM1/TSLC1 is similar to that of another important family 
of IgCAM, namely the nectins, and so it is also called Nectin-like molecule 2 (Necl-2) [49]. 
The extracellular domain of CADM1 mediates the formation of homodimers or 
heterodimers with other CAM members, including Necl-1, CRTAM (class-I MHC-restricted 
T cell-associated molecule) and Nectin-3 to regulate cell adhesion [49, 50]. 
The cytoplasmic domain contains the protein 4.1 binding motif and directly 
associates with DAL-1, a gene product of another lung tumor suppressor belonging to the 
protein 4.1 family and interacts with the actin filament through an anchoring protein, DAL1 
[53]. 
The cytoplasmic C-terminal sequence harbors a PDZ-domain protein-interaction 
sequence that is homologous to that of the synaptic cell-surface proteins neurexin and 
syndecan, which bind to the PDZ-domain protein CASK and syntenin [52].  Via the PDZ-
binding domain CADM1 interacts with pals2, and MPP3 [52]. 
CADM1's role as a cell adhesion molecule has been well established. Molecules 
that are identical to human CADM1 or its murine orthologues have been found to play key 
roles in the adhesion of spermatogenic cells to Sertoli cells, mast cells to fibroblasts, 
presynaptic cells to postsynaptic cells, tumor cells to natural killer (NK) cells, and antigen-
presenting cells to CD8+ T cells through homophilic or heterophilic interactions [42, 43, 46, 
54, 55]. Its role as a tumor suppressor, has been shown in a variety of cancers of epithelial 
origin [40]. Also, Mao et al. reported that high CADM1/TSLC1 expression levels from a 
recombinant adenovirus vector (Ad-TSLC1) inhibited cell proliferation and induced 
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apoptosis in A549 cells [56]. 
Studies in nude mice have demonstrated that re-expression of CADM1 suppresses 
in vivo tumorigenicity of NSCLC and nasopharyngeal carcinoma cell lines [56, 57]. 
Apoptosis induction, as well as the formation or maintenance of an epithelial cell 
structure through homophilic interaction, is one of the possible molecular mechanisms of 
CADM1/TSLC1 in the tumor suppression of carcinomas. 
In contrast, CADM1/TSLC1 has been found to be ectopically expressed in adult T-
cell leukemia (ATL), and could be implicated in tumor invasion through interactions of the 
leukemia cells with the endothelial cells [58]. Another interesting study challenging 
CADM1's role as a tumor suppressor is one by Kikushi et al. They studied a splicing variant 
of CADM1 present in Small Cell Lung Cancer and their results suggest that CADM1 
enhances the malignant features of SCLC, as is observed in ATL, and could provide a 
molecular marker specific to SCLC [59].  
It is now known that CADM1/TSLC1 is expressed universally in human tissues and 
is frequently silenced in a variety of human carcinomas, such as lung, prostate, liver, 
stomach, pancreatic and breast carcinoma [48, 56].   
Besides mutations and deletions, DNA methylation of CpG islands in the promoter 
region of cancer-related genes is a frequently acquired epigenetic event in the pathogenesis 
of many human malignancies leading to gene silencing. So far, aberrant methylation 
(referred to as methylation) has been described for several genes in various malignancies 
including lung cancer [60]. 
Promoter methylation of the CADM1/TSLC1 gene was demonstrated in NSCLC, 
pancreatic cancers, hepatocellular carcinoma, and prostate cancers, cancers from the 
esophagus, stomach, nasopharynx, breast, and uterine cervix, as well as meningioma, and 
seems to be the main mechanism underlying the expression silencing [41, 49, 60-62]. 
Furthermore, methylation or loss of CADM1 expression was observed preferentially 
in tumors at advanced pathological stages rather than in early stages and found to be 
associated with tobacco smoking  [63, 64]. Fukami et al. demonstrated that CADM1 
promoter methylation was significantly associated with tumor progression of NSCLC from 
pT1 to pT2 and from stage Ia to IIb  [61].  And Heller et al. showed that promoter methylation 
also occurred more frequently in tumors at grade 3, compared with tumors at grade 1 or 2 
in breast cancer [65].  
In an immunohistochemical study using a specific antibody against CADM1/TSLC1, 
Uchino et al. demonstrated that CADM1/TSLC1 expression was inversely correlated with 
advanced disease stage, lymph node involvement, lymphatic permeation, and vascular 
invasion. 4-year survival and disease-free survival are significantly shorter in patients with 
lung adenocarcinoma lacking CADM1 expression [66]. 
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For all that’s been previously said, it seems clear that CADM1 plays an important 
role in cancer development, especially in NSCLC since it is downregulated in most cases 
and appears to be correlated with tumor progression, but can it be used as a biomarker?  
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2. Objectives 
 
2.1. Main Objective 
  
The aim of the present study is to evaluate if Cadm1 expression levels can be used 
as biomarker for diagnosis and/or prognosis for NSCLC patients.  
 
Thereby, the present study can be divided in two different parts:  
 
2.2. Specific Objectives 
 
1. Assess Cadm1’s expression levels in peripheral blood as a possible diagnostic 
marker for NSCLC; 
2. Evaluate the association between Cadm1’s expression levels in peripheral blood 
and tumor progression, namely 1-year survival. 
  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and Methods  
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3. Material and Methods 
 
3.1. Patient selection and sample collection 
 
3.1.1. The first part of this work consisted of a hospital-based case-control study 
involving 141 individuals (89 NSCLC patients and 52 healthy individuals) all Caucasian, 
from the north of Portugal. All participants signed an informed consent according to the 
Helsinki declaration. 
The case group consisted of 69 males and 20 females all Caucasian with non-small 
cell lung cancer diagnosed and treated at the Portuguese Institute of Oncology of Porto 
(mean age = 61.2; SD=15.7). After patients signed an informed consent according to the 
Helsinki declaration a blood sample was collected before any medical intervention. 
All the demographic and histopathological data were collected from the clinical files 
of each patient and the staging of each patient was made according to the AJCC TNM 
classification system 2010 (7th edition). 
For the control group, 52 healthy Caucasian individuals with no history of cancer 
(mean age = 50.22; SD=17), were randomly recruited from the north of Portugal. All 
demographic data were collected through a written form, authorized by the ethics committee 
of the Portuguese Institute of Oncology of Porto, and signed by each individual, according 
to the Helsinki declaration. 
All the clinicopathological and demographic data are described in table 1. 
Approximately 8 ml of peripheral blood were collected from all individuals throught 
a standard method of intravenous collection with EDTA tubes. The blood tubes were 
centrifuged 5 minutes at 2800 rpm in order to separate the peripheral blood cells and then 
preserved in Tripure ® (Roche) at 80ºC. 
 
3.1.2. The second part consisted of a follow-up study involving the 89 NSCLC 
patients from the case group of the first part. All the clinicopathological data are described 
in table 1. 
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Table 1 Clinicopathological and demographic characteristics of the participants 
  Cases Controls 
  (n=89)  (n=52) 
  n %  n % 
Gender       
Masculin 69 77.5  17 32.7 
Feminin  20 22.5  35 67.3 
 Total 89 100.0  52 100.0 
Age       
Mean ± SD 61,2 ± 15,7  50,22 ± 17  
Histology      
SCC 32 36.0    
Non-SCC 57 64.0    
 Total 89 100.0    
Stage       
I  3 3.4    
II  1 1.1    
III  36 40.4    
IV  49 55.1    
 Total 89 100.0    
Smoking       
Smokers and Ex-
Smokers 
 66 74.2 10 19.2 
Non Smokers  22 24.7 41 78.9 
No information  1 1.1 1 1.9 
    Total 89 100.0 52 100.0 
 
3.2. RNA extraction and cDNA synthesis 
After collecting the samples, the RNA was extracted from the peripheral blood cells 
(preserved in Tripure®) using an extraction kit (GeneJetRNAPurification KIT, Thermo 
Scientific®) and following the manufacturer's instructions. The concentration and purity of 
the isolated RNA were measured at 260 and 280 nm using the NanoDrop® ND-1000 
spectrophotometer. 
The mRNA samples were then used as template for cDNA synthesis using a High 
capacity RNA-to-cDNA kit from Applied Biosystems®, according to manufacturer’s 
instructions. 
 
3.3. Cadm1 relative quantification 
The Cadm1 mRNA expression was analyzed by quantitative real-time PCR. The 
reactions were carried out on a StepOneTM qPCR -  Real-Time PCR machine, containing 
1X Master mix (Applied Biosystems®), with 1X probes (TaqMan® Gene Expression Assay – 
Hs00942509_m1 – Applied Biosystems®), cDNA sample and GUSβ endogenous control 
(TaqMan® Pre-Developed Assay – NM-000181 – Applied Biosystems®) which was used to 
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normalize the results regarding the biomarkers, since it presents a constant expression level. 
Data analysis was made using StepOneTM Sofware v2.2 (Applied Biosystems®) with the 
same baseline and threshold set for each sample, in order to generate threshold cycle (Ct) 
values for all the mRNAs. The mRNAs quantification (Cadm1 and Gusβ) was performed in 
duplicate and negative control lacking cDNA was included in all reactions. 
The results were confirmed by two independent investigators. 
 
 
 
3.4. Statistical Analysis 
 
For the statistical analysis we used IBM®SPSS®Statistics software for Windows 
(Version 22.0). The 2-ΔΔCt method (Livak method) and the t’ Student test were used to 
evaluate the differences in the expression levels of the normalized mRNA. 
Chi-square analysis (X2) was used to compare the categorical variables. p values 
under 0,05 were considered statistically significant. 
The probability associated of between our variables and NSCLC is indicated by the 
Odds Ratio (OR) using a 95% confidence interval (CI 95%). 
We also analyzed a multivariate logistic regression to obtain the OR and respective 
CI 95% for the influence of the different variables in the risk of developing NSCLC 
metastasis adjusting for possible confounding variables. 
The Kaplan-Meier method and Log-rank test were used to compare the mRNA 
expression profile influence in the patients’ one-year survival. 
Amplification plot 
Figure 4 Amplification curves of Cadm1’s relative expression 
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The odds ratio (OR), specificity, sensitivity, positive predictive value (PPV), negative 
predictive value (NPV), as well as the receiver operating characteristic (ROC) curves were 
used to evaluate the potential of Cadm1 as a NSCLC biomarker. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results  
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4. Results 
  
4.1. Cadm1 as a diagnostic marker for NSCLC 
4.1.1 Association between Cadm1 expression levels from peripheral blood 
and NSCLC. 
 
In order to clarify and evaluate the effective potential of using Cadm1’s expression 
levels in circulation as a NSCLC biomarker, a ROC curve was constructed and odd ratio 
(OR), specificity, sensitivity, positive predictive value (PPV) and negative predictive value 
(NPV) were determined. Using the results of the ROC curve, an analysis was made on the 
test performance with respect to the different threshold values, and a cut-off value was de-
termined corresponding to ∆Ct=5.13. Values under the cut-off point were determined Low 
Cadm1 and values above the cut off represented the High Cadm1 expression group. 
The odd ratio (OR) represents the odds of an individual having NSCLC, given that 
they have Low Cadm1 expression levels compared to the odds of the individual being 
healthy, given that they have High Cadm1 expression [67]. The specificity reveals the prob-
ability of detecting High Cadm1 given that the individual tested is healthy [68]. On the other 
hand, the sensitivity reflects the proportion of the detection of Low Cadm1 in NSCLC sam-
ples [68]. The positive predictive value (PPV) reveals the probability of having NSCLC 
among those who have Low Cadm1 expression levels, whereas the negative predictive 
value (NPV) indicates the probability of being NSCLC-free among those who have High 
Cadm1 expression levels [68].   
The frequencies of Cadm1 expression levels in the control (n=52) and case groups 
(n=89) are described in table 2. According to our results, the majority of participants with 
High Cadm1 were in the control group (61.5%) and most of the participants with Low Cadm1 
expression belonged to the case group (57.3%). 
There is a statistical significance between the groups (OR=2.147; CI 95%=1.068-4.32; 
p=0.031). Moreover, the specificity of Low Cadm1 expression levels is 61.5%, and the sen-
sitivity is 57.3%. Additionally, the PPV value is 72% and NPV is 54%. 
 
Table 2 Frequency of Cadm1 expression levels in the control and NSCLC groups. 
  Cases (n=89) Controls (n=52) 
OR CI95% p 
  n % n % 
High Cadm1  38 42.7 32 61.5    
Low Cadm1  51 57.3 20 38.5 2.147 1.068-4.32 0.031 
p- p value from X2 test; OR- Odds Ratio; CI 95% - Confidence Interval at 95% 
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In order to better visualize these differences we created the graphic below where it is clear 
that the higher percentage of individuals with low Cadm1 expression levels belong to our 
case group and the higher percentage of individuals with high Cadm1 expression levels 
belong to the control group. 
 
 
To have a better understanding of our sensitivity and specificity values, we compared our 
study with other methods currently in use for diagnosing NSCLC. 
 
Table 3 Comparison of specificity and sensitivity values for the currently used methods for 
diagnosing NSCLC 
Screening method Specificity (%) Sensitivity (%) References 
Cadm1 expression 
levels 
61.5 57.3 Current work 
Low Dose CT 92.6 / 98.3 88.9 / 94.6 [69] / [70] 
Chest x-ray 78.3 92.6 [69] 
Panel of 6 antibodys 
agains 6 tumor related 
antigens 
89-91 36-39 [70] 
 
These results suggest that assessing Cadm1’s expression levels in peripheral blood may 
be a potential diagnostic marker for NSCLC. 
Figure 5 Percentage of participants (cases and controls) 
corresponding to the different Cadm1’s expression profiles 
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To further evaluate the potential of monitoring Cadm1 expression levels to diagnose NSCLC 
we studied the association between gender and the gene's expression levels (table 4) to 
eliminate possible confounding bias. According to our results, Cadm1’s expression levels 
are independent of gender. 
 
Table 4 Logistic Regression for Cadm1 expression 
  
HR CI 95% p 
Cadm1 High/Low 0.401 0.181-0.887 0.024 
Gender 7.639 3.459-16.871 <0.001 
p- p value from X2 test; HR- Hazard Ratio; CI 95% - Confidence Interval at 95% 
 
 
 
4.2. Cadm1 influence in tumor progression and NSCLC advanced 
stages  
 
4.2.1 Association between Cadm1 expression levels and NSCLC advanced 
stages 
To study whether there was an association between Cadm1 expression levels and 
the evolution of the tumor we analyzed the expression in early stages (I and II) versus ad-
vanced stages (III and IV) as described in table 5. We couldn’t find any differences with 
statistical significance between the groups (OR=2.30; CI 95%=0.231-23.147; p=0.464). 
 
Table 5 Association between Cadm1 expression levels and tumor stages 
 Stage I + II Stage III + IV Total OR CI 95% p 
Cadm1 mRNA n (%) n (%) n (%)    
High 1 (25.0) 37 (43.5) 38 (42.7) - -  
Low 3 (75.0) 48 (56.5) 51 (57.3) 2.30 0.231-23.147 0.464 
p- p value from X2 test; OR- Odds Ratio; CI 95% - Confidence Interval at 95% 
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4.2.2. Association between Cadm1 expression levels and NSCLC long 
distance metastasis selecting for possible confounding variables 
 
 
 
4.2.2.1. Selecting for Gender 
 
In order to eliminate gender as a possible confounding variable we analyzed the 
differences in Cadm1’s expression levels between non-metastatic stages and metastatic 
stages regarding gender. We couldn’t find any differences with statistical significance 
between the groups in neither female (OR=2.667; CI 95%=0.237-30.066; p=0.417) or male 
(OR=1.200; CI 95%=0.466-3.093; p=0.706). 
 
Table 6 Association between Cadm1 expression levels, metastization and gender 
Gender Cadm1 
Stage I, II and III Stage IV OR CI 95% p 
n (%) n (%)    
Female 
High 1 (14.3) 4 (30.8) -   
Low 6 (85.7) 9 (69.2) 2.667 0.237-30.066 0.417 
Male 
High 15 (45.5) 18 (50.0) -   
Low 18 (54.5) 18 (50.0) 1.200 0.466-3.093 0.706 
p- p value from X2 test; OR- Odds Ratio; CI 95% - Confidence Interval at 95% 
 
 
 
4.2.2.2. Selecting for Smoking status 
 
In order to eliminate the smoking status as a possible confounding variable we 
analyzed the differences in Cadm1’s expression levels between non-metastatic stages and 
metastatic stages regarding smoking status. We couldn’t find any differences with statistical 
significance between the groups in neither Smoking (OR=1.466; CI 95%=0.554-3.882; 
p=0.441) or non-smoking (OR=1.200; CI 95%=0.166-8.659; p=0.856). 
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Table 7 Association between Cadm1 expression levels, metastization and smoking status 
Smoking 
status 
Cadm1 
Stage I, II and III Stage IV OR CI 95% p 
n (%) n (%)    
Smoking 
High 13 (41.9) 18 (51.4)    
Low 18 (58.1) 17 (48.6) 1.466 0.554-3.882 0.441 
Non-
smoking 
High 2 (25.0) 4 (28.6)    
Low 6 (75.0) 10 (71.4) 1.200 0.166-8.659 0.856 
p- p value from X2 test; OR- Odds Ratio; CI 95% - Confidence Interval at 95% 
 
 
 
4.2.2.3. Selecting for Histology  
 
 
In order to eliminate histology as a possible confounding variable we analyzed the 
differences in Cadm1’s expression levels between non-metastatic stages and metastatic 
stages regarding the different histologic subtypes. We couldn’t find any differences with 
statistical significance between the groups in neither Squamous Cell Carcinoma (OR=1.469; 
CI 95%=0.350-6.168; p=0.598) or Non-Squamous Cell Carcinoma (OR=1.067; CI 
95%=0.360-3.159; p=0.907). 
 
 
Table 8 Association between Cadm1 expression levels, metastization and histologic 
subtype 
Histologic 
subtype 
Cadm1 
Stage I, II and III Stage IV OR CI 95% p 
n (%) n (%)    
SCC 
High 7 (36.8) 6 (46.2)    
Low 12 (63.2) 7 (53.8) 1.469 0.350-6.168 0.598 
Non-SCC 
High 9 (42.9) 16 (44.4)    
Low 12 (57.1) 20 (55.6) 1.067 0.360-3.159 0.907 
p- p value from X2 test; OR- Odds Ratio; CI 95% - Confidence Interval at 95% 
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Figure 6 One-year survival by Kaplan-Meier for non-metastatic (A) and metastatic (B) NSCLC according 
to Cadm1’s expression levels in the blood. 
4.3. The influence of Cadm1 expression levels in 1year survival rates 
 
 
When analyzing the association between Cadm1’s expression levels with one-year 
survival, distinguishing non-metastatic (stages I, II and III) and metastatic (stage IV) we 
observe different results. According to figure 6A (non-metastatic) there is a difference with 
statistical significance in 1-year survival rates of patients with Low Cadm1 versus patients 
with High Cadm1 (p=0.016). In figure 6B (metastatic) the difference between the two groups 
(High Cadm1 and Low Cadm1) doesn’t have statistical significance (p=0.751). 
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5. Discussion 
In the past years it has become clear that the key to lower cancer mortality rates is 
in early diagnosis and personalized therapy. Because cancer is a very complex disease, 
finding a specific marker for early diagnosis is complicated and finding a specific target for 
treatment has proven difficult for most tumors.  
With the consistent increase in lung cancer incidence and low survival rates it has 
become imperial to find tools that allow early diagnosis. It is clear that people with tumors 
diagnosed in early stages have far better survival rates than those whose tumors were in 
more advanced stages. For lung cancer, one of the obstacles to early diagnosis is the fact 
that symptoms only appear in more advanced stages and a major hurdle in the attempts to 
improve the survival of these patients has been the lack of a simple, non-invasive and 
effective test for early prediction and for monitoring therapeutic efficacy [21, 29].  
One potential marker for NSCLC development is CADM1. Even though Cadm1 is 
expressed in a variety of normal tissues, nowadays, CADM1 is well established as a tumor 
suppressor, not only in lung cancer, but in different tumors and appears to be downregulated 
in more advanced stages of the disease [48-53]. This downregulation is mostly due to 
promoter methylation but can also be the result of LOH.  Because CADM1 is an adhesion 
molecule, it seems logic that its expression is lower when tumor has metastasized, since 
this process requires cell detachment from the primary tumor.  
The use of a biomarker for early detection and for monitoring disease progression 
implies that with a simple test we can differentiate an affected patient from a person without 
the disease. This means diagnosing tumors in earlier stages that consequently are easier 
to treat and also, adjust therapy strategies according to each patient’s response.  
To the best of our knowledge, our study is the first to measure Cadm1 levels in 
peripheral blood. All the others report the use of tissue samples obtained directly from the 
tumor to quantify the molecule. When measuring Cadm1’s levels in circulation we’re 
referring to its expression in blood cells and not plasma or serum. 
With this in mind, we established two main goals in order to evaluate the potential 
of using this method for early diagnosis, monitoring disease progression and evaluate 
clinical outcome: the first was to determine if there was an association between circulating 
mRNA levels of the CADM1 gene and non-small cell lung cancer in order to validate Cadm1 
as a good diagnostic marker; the second was to study the association of circulating 
CADM1’s expression levels and tumor progression and clinical outcome. 
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5.1.  Association between Cadm1 expression levels from peripheral 
blood and NSCLC. 
 
In the beginning of the process of carcinogenesis the cell must undergo a change, 
genetic and / or epigenetic, which may lead to changes in gene activity resulting in the 
rupture of the homeostatic balance [71]. Some of these alterations lead to inactivation of 
tumor suppressor genes (TSGs) and the effect of their inactivation plays a major role in 
cancer and has been described for several genes in various malignancies. 
CADM1 is a TSG that has been reported to be functionally involved in pulmonary 
carcinogenesis and that is highly methylated in most NSCLC cases and inactivation of this 
gene by promoter methylation has been proposed as a candidate marker for early lung 
cancer detection [40, 72]. 
Even though the process through which Cadm1 acts to suppress tumorigenesis is 
still not clear, being a tumor suppressor it seems logic to find higher levels of Cadm1 in 
healthy individuals compared with patients with cancer. 
According to our results, there is a difference with statistical significance between 
our case and control groups: individuals with Low Cadm1 expression levels, have a higher 
probability of being diagnosed with NSCLC (OR=2.147; CI95%=1.068-4.32; p=0.031) when 
compared with individuals with High Cadm1 expression levels. The majority of our control 
group had High Cadm1 expression levels (61.5%) while in NSCLC group, the majority 
presented with Low Cadm1 expression levels (57.3%). 
If CADM1 is a TSG, healthy individuals will have High Cadm1 expression levels. 
Patients with NSCLC, however, will have lower Cadm1’s expression levels since the 
disruption of the balance between oncogenes and tumor suppressor genes is a crucial step 
for carcinogenesis. With CADM1 downregulated, there is a reduction of the signals to stop 
cell growth and a decreasing in the level of cell adhesion which allows the tumor to develop 
[73].  
The diminished levels of Cadm1 in the blood cells of patients with NSCLC compared 
to healthy individuals may be due to different factors. It has  been proposed that Cadm1 
interacts with the immune system [49, 74], so it is logical to suppose that low Cadm1’s 
expression in the blood cells of NSCLC patients is the result of the interaction between 
tumor cells and blood cells. Tumor cells signal the cells in circulation to lower their Cadm1 
expression levels. If these blood cells signal other cells to lower their Cadm1 expression, 
the result could be the establishment of a microenvironment with a reduced tumor 
suppressor activity consequently promoting tumor development, invasion and metastization. 
How this interaction works, and the pathways leading to Cadm1 decrease in the blood cells 
is still unknown.  
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On the other hand, we can also suggest that the difference in Cadm1 expression in 
circulating blood cells between healthy individuals and NSCLC patients is the cause for 
tumor formation instead of a consequence of the tumor. It is possible to assume that 
because individuals from our case group had a polymorphism that resulted in lower Cadm1 
expression, they were more susceptible to develop NSCLC than our control group. If this 
was the case, it wouldn’t be the tumor modulating Cadm1’s expression levels in circulation. 
The fact that those people had less Cadm1 by default would be the reason to why they are 
more susceptible to develop NSCLC. Weyden et al. showed that Cadm1-null mice died 
significantly faster than their wildtype littermates due to the spontaneous development of 
tumors at an earlier age, which supports our suggestion [75].  
Whatever the cause for the difference of expression levels, our results support the 
potential of using Cadm1 as a diagnostic biomarker with a sensibility of 57.3%, specificity 
61.5%, PPV of 72% and NPV of 54%. 
At the present time, there isn’t an ideal screening method for lung cancer and the 
methodologies used are either expensive, or have side effects, or are not accessible or 
applicable to everybody. When compared to the current methods used, Cadm1 expression 
levels in peripheral blood seems to have low specificity and sensitivity (table 3). However, 
it is important to note that this is a non-invasive method, with no side effects (contrary to 
those of CT scans and X-Ray), it’s less expensive, faster to obtain results and applicable to 
everyone. Having a PPV of 72% means that an individual who has Low Cadm1 expression 
levels in blood cells has a 72% chance of already having NSCLC and should therefore be 
recommended for further diagnostic tests. Based on these results Cadm1 has a potential to 
be a remarkable biomarker for NSCLC through a simple blood test.   
 
5.2 Association between circulating Cadm1 expression levels and 
tumor progression and clinical outcome 
 
5.2.1. Circulating levels of Cadm1 and tumor progression  
 
There is still a lot to understand about the role CADM1 plays in tumor development 
and the pathways it is involved in, but many different studies have reported a correlation 
between loss of Cadm1 expression and advanced stages (poor prognosis) and metastasis 
[50, 63, 66]. Inhibition of Cadm1 in the tumor was proven to be important in metastasis 
formation in different studies and its re-expression found to prevent metastasis formation.  
Our results, however, didn’t show an association between Cadm1 circulating levels 
and tumor progression. We compared Cadm1’s expression levels for early stages (stages 
I and II) against advanced stages (III and IV) and found no statistical association (p=0.464; 
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OR=2.30; CI95%=0.231-23.147). This means that there are no differences in Cadm1’s 
circulating levels during disease progression, and so, evaluating Cadm1’s expression in the 
blood doesn’t appear to be a good method.   
Since Cadm1 has been proposed to be associated with metastasis formation, and 
even though we obtained no association between Cadm1 and progression from early to 
advanced stages, we decided to check if there was any difference between Cadm1’s 
expression levels in patients with non-metastasized tumors (stages I, II and III) versus 
metastasized (stage IV).   
Again, we didn’t find any association even when we eliminated possible bias due to 
confounding variables (gender, smoking status and histologic subtype).  
Since CADM1 is a tumor suppressor gene that induces apoptosis and inhibits tumor 
growth, it makes sense that there is a decreased expression with tumor progression [56]. 
Less Cadm1 means less apoptotic signals and growth inhibition. Also, less Cadm1 means 
less cell adhesion, which is one of the initial steps to metastasis.  
However, when measuring Cadm1’s levels in circulation we’re referring to its 
expression in blood cells that may not be representative of tumor behavior.  
These results suggest that the interaction between tumor cells and blood cells, that 
decreases Cadm1 expression in the latter, happens in the beginning of the carcinogenic 
process since they don’t show any difference with tumor progression or metastasis 
formation. Cadm1 seems to be more important for disease initiation rather than progression, 
and the reason why Cadm1’s expression levels change in tumor cells and not in blood cells 
in more advanced stages is due to different factors involved with tumor development. 
This explanation is still plausible if we consider the hypothesis of the existence of a 
putative polymorphism for this gene. If there is indeed a difference in the gene that causes 
lower expression levels in some individuals, the tumor progression won’t affect Cadm1 
levels in other cells beside tumor cells.  
 
5.2.2. Circulating Cadm1 levels and clinical outcome 
 
Lastly, we decided to evaluate the influence of Cadm1 in one-year survival rates. 
The prognosis of patients with stage IV NSCLC is still poor, most large-phase III trials have 
shown a median survival time from 8 to 10 months and 1-year survival rate of 30%–35%, 
that drops to 0%–1% for the 5-year survival rate [76, 77].  
It is clear that patients with non-metastatic NSCLC and Low Cadm1’s expression 
levels have a worst survival rate than those with High Cadm1 (p=0.016) Yet the same isn’t 
true for stage IV. In this case, Cadm1 apparently doesn’t affect one-year survival (p=0.751) 
(Figure 6). 
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Relative to non-metastatic tumors, our results show that NSCLC patients with Low 
Cadm1 have a worst prognosis than those who have High Cadm1 which is in accordance 
to what should be expected: individuals with low Cadm1 levels have less cell adhesion, less 
tumor suppressor activity and therefore are more likely develop into a more aggressive 
tumor culminating in worst prognosis [75].  
For patients with tumors that have already metastasized, we don’t see any 
differences in survival between patients with low circulating levels against high circulating 
levels. As stated previously, CADM1 is associated with metastasis formation since it codes 
for an adhesion molecule, and in order for a tumor to metastasize its cells need to loose 
adherence. But the fact that Cadm1’s expression levels don’t seem to be relevant for 
survival in stage IV patients suggests that after metastization, CADM1 stops being 
significant. In this stage there are other factors that have a bigger effect on survival. 
To conclude, according to our study, the assessment of Cadm1’s expression levels 
in the blood seems to be a good diagnostic marker for NSCLC. It’s a simple method that 
allows to differentiate between healthy individuals and NSCLC patients with statistical 
significance.  
On the other hand, we didn’t find evidence that this is a good method to analyze 
tumor progression. But evaluating Cadm1’s expression levels in the blood seems to 
possibly be a good prognostic factor for non-metastatic tumors since there are different 
expression profiles between metastatic and non-metastatic tumors.    
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6. Conclusion and future perspectives 
 
The study of potential biomarkers has become one of the most invested areas in 
cancer research. In the recent years, knowledge about cancer biomarkers has increased 
tremendously providing great opportunities for improving the management of cancer 
patients by enhancing the efficiency of detection and efficacy of treatment.  
The reality of the non-existence of a standard screening test for the early detection 
and follow-up in NSCLC has been haunting oncologists for the past years since lung cancer 
(specifically NSCLC) is one the most lethal neoplasia. The future of cancer therapy lies in 
the use of biomarkers that offer the potential to identify and treat cancer years before it is 
either visible or symptomatic. Exploring the presence of such markers that does not require 
the tumor tissue to detect them, but are obtained from a simple blood sample will not only 
facilitate easy detection without even minimal surgical procedure, but will also identify 
candidates for population based screening. This is a major improvement and believed to be 
the best way to lower incidence and mortality rates for lung cancer.  
Being a cell adhesion molecule known to suppress tumor development that is 
silenced in most lung cancer patients, Cadm1 gene has been in the spotlight for a potential 
lung cancer biomarker for a couple of decades. Its role as a tumor suppressor is well 
established for various types of cancer even though the pathways involving this process 
aren’t clear. Also, the correlation between lower Cadm1 expression and lung carcinogenesis 
has proven to be strong. A better and clearer understanding of how Cadm1 works, the 
pathways it is involved in, the molecules it interacts with etc. are a few of the subjects that 
need intensive research. 
With this work we’ve demonstrated that there is a relevant difference of circulating 
Cadm1 levels between healthy individuals and cancer patients that could be used as a 
screening test for NSCLC. We proposed two scenarios for the diminished expression seen 
in cancer patients compared to healthy individuals: The tumor, with lower Cadm1, interacts 
with the cells in circulation signaling them to lower Cadm1’s levels in order to promote a 
decrease in the tumor suppressor activity of the tumor surrounding cells; Or, there is a 
difference in Cadm1 expression levels due to a polymorphism in the gene that results in a 
lower Cadm1 expression by default, making that person more susceptible to develop 
NSCLC compared to those who don’t have the polymorphism.  
This opens many possible courses of investigation for the future.  
Analyzing our sample for a possible polymorphism in the CADM1 gene and 
determine if there is an association between that polymorphism and risk for developing 
NSCLC and clinical outcome would be of interest.   
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To validate the hypothesis that our data is the result of tumor interaction with blood 
cells it would be interesting to analyze both tumor tissue and blood samples from each 
individual in order to evaluate a possible correlation between them. 
Also, knowing more about what triggers Cadm1 silencing in tumor initiation may 
prove essential to understand it’s role in tumor formation and development.  
Another interesting idea would be testing Cadm1’s expression levels in patients 
before and after treatment to understand treatment efficacy and the possibility of using 
Cadm1 as a marker for monitoring tumor development and treatment efficacy.  
There is a lot we don’t know about this molecule and its role in lung cancer 
development, but according to our study, the assessment of Cadm1’s expression levels in 
the blood seems to potentially be a good diagnostic marker for NSCLC. It’s a simple, fast 
and accessible method that allows to differentiate healthy individuals from NSCLC patients. 
Continuing this work is essential to understand Cadm1 and its role in NSCLC.  
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